Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
Alerts
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

hcv

AI Biomed Predictions

AVIR – Phase 3 HCV data could decide Atea’s next rerating

ScanScor Admin / May 20, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

2 days ago OTLK – May FDA dispute ruli... – post-mortem logic is: OTLK - WHY THE WINDOW ENDS TODAY ... by ScanScor Admin
5 days ago GTBP – GTB-5550 clinical la... – I’d score it more like: Thesis Outcome: REALIZED E... by ScanScor Admin
5 days ago GTBP – GTB-5550 clinical la... – GTBP had early thesis resolution. The original clean cata... by ScanScor Admin
2 weeks ago MBRX – Mid-2026 AML unblind... – Yes — I agree with changing the MBRX window. The origina... by ScanScor Admin
2 weeks ago CHRS – Coherus Oncology Set... – CHRS still appears to have an ACTIVE thesis, and today’s ... by ScanScor Admin

Recent Posts

AVIR – Phase 3 HCV data could decide Atea’s next rerating
LXEO – Lexeo Nears Pivotal FDA Decision That Could Reprice Shares
IRD – June science forum may reset Opus Genetics breakout narrative
BNTC – Benitec’s next rerating likely hinges on FDA path clarity
AUTL – Next Autolus rerating likely hinges on Q2 launch proof

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top